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ABSTRACT
Aging and diseases associated with aging is a condition associated with old age. An important approach to maintaining health status and physical 
examination in geriatric patients is very important, including nutrition problems, sight, hearing, urine containment, balance and fall prevention, 
osteoporosis, and polypharmacy. The use of polypharmacy will give some impact on the elderly, including increasing the improper treatment, adverse 
drug reactions (ADRs), and some of the problems that affect the changing nature of the pharmacokinetics and pharmacodynamics of drugs. Aging in 
the elderly with some illness, may potentially lead to get more number of medicines, leading to inappropriate prescribing patterns, and contributing 
to adverse drug reactions and hospitalization. This review will describe the effect of polypharmacy in elderly patients.
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INTRODUCTION
Health development is directed to increase awareness, willingness, 
and ability of healthy life for everyone to improve the health 
of as high as can be realized. The impact of the success of health 
development characterized by rising life expectancy, lowered 
mortality rate and the birth mother [1]. According to the Central 
Bureau of Statistics Indonesia in 2013, life expectancy in Indonesia 
is 73 years for women and men is 69 years. National Development 
Planning Agency projected life expectancy in Indonesia in 2025 may 
reach 73.6 years [2].
In the United States, the elderly population aged over 65 years to reach 
13% of the total population, but total consumption of drugs accounted 
for 33% of all prescriptions. In 2040, 25% of Americans are expected to 
consume the drug reaches 50% of all prescriptions. While in Singapore, 
in 2030 the elderly population is projected to 18.4% of the total 
population in Singapore [3].
The pattern of prescribing for someone with multiple diseases must 
be based on the best available evidence. The use of polypharmacy 
will give some impact on the elderly, including an increase in 
inappropriate treatment, adverse drug events (ADEs), and some 
of the problems that are affected by changes in pharmacokinetics, 
pharmacodynamics, and comorbidities. Polypharmacy is defined 
as at least one of the administrations of medicinal drugs are not 
indicated [4]. This definition requires an assessment of the drug 
and drug compliance were used. Providing a drug with an incorrect 
indication, drug duplication, will contribute to polypharmacy. For 
example, a proton-pump inhibitor used as prophylaxis in hospitalized 
patients to prevent stress ulcers. If the treatment is continued when 
the patient was discharged from the hospital, then this drug would 
be considered unnecessary given because there was no indication. 
Polypharmacy associated with significant consequences such as side 
effects, noncompliance drug use, and drug interactions (DIs), as well 
as an increased risk of geriatric syndromes [5]. Polypharmacy also 
contributes to the accumulation of the drug in the elderly, resulting in 
serious side effects of drugs [6]. Various studies indicate potentially 
inappropriate medication (PIM) is caused by polypharmacy. Thus, this 
review will evaluate the impact of polypharmacy in the elderly, and 
PIMs.
POPULATOIN OF ELDERLY
United States defines the elderly as individuals who have 65-74 years 
of age, who have health problems and diseases, dependence on others 
as well as the problems the function and dysfunction of organs, while a 
very old age is an individual over the age of 85 years (the “oldest old” 
>85 years). According to statistical data, the geriatric population and 
the elderly will continue to increase, this increase will continue with 
a significant amount. The population in 2004 was 36.2 million and 
increase to 46.2 million in 2014, reaching up to 28%. When projected in 
the year 2060 will reach 98.2 million. Meanwhile, people who are older 
than 85 years has reached 6.2 million in 2014, will increase continuously 
and is projected to be 14.6 million in 2040 [7]. In Germany, the elderly 
population and which has very old has reached 4, 5 million people, and 
5.4% were aged 80 years or more. This population will continue to 
grow in the past decade. In Italy, they were very elderly (>85 years of 
age) is growing rapidly. Increased life expectancy and improving health 
in the elderly is an indicator of a country’s success in prevention of 
various diseases associated with the aging process [8]. The elderly aged 
60 years and older is increasing rapidly. In 2010, the world’s population 
aged 60 and over was 11% and in 2030, will reach up to 16%. In 2030, 
Europe has been estimated that the percentage of the population aged 
60 will reach up to 29%. They have special problems due to aging, 
changes in physiological functions, some diseases of the elderly, which 
can cause various health problems. As a result, the elderly will consume 
more drugs or polypharmacy, which can lead to serious risks and 
complications [9].
The increasing of health and welfare of the population will have an 
effect on the increase in life expectancy in Indonesia. According to the 
Indonesian Central Bureau of Statistics, it is estimated that in 2035 there 
are five provinces with the percentage of the population 65 years and over 
were highest at 14.9%, Central Java, East Java, 14.1%, 14.0% Yogyakarta, 
Bali 12.1%, and North Sulawesi 12.0%. Thus, the number of people 
65 years and over in the province has reached more than 10% (of the 
total estimated population of Indonesia in 2035 amounted to 305 million 
people). The older population in 2035 is predicted to reach 15.77% [2].
CHANGE OF AGING
Aging is a multidimensional process. Normal aging and diseases 
associated with aging is an integral condition. Typically, the aging 
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process will lower physiological functions, for example; decreased 
bone density, osteoarthritis, and suffering cataract lens, while the 
diseases associated with old age, but does not occur in all people (aging 
probabilistic) is dementia, hypothyroidism, stroke, and congestive heart 
failure (CHF). Various studies of modern molecular and cellular biology 
have demonstrated the mechanism of aging, such as DNA damage, 
oxidative materials, free radical, catastrophic error, the aging process, 
apoptosis, immune, neuroendocrine, and others. Decrease integrative 
cell with a specific function (pituitary, thyroid, adrenal, pancreas, and 
glands gonads) cause abnormalities of homeostasis. Decreased organ 
function in the elderly is more prone to various diseases so that the 
elderly will receive many medications (polypharmacy) [10,11].
Androgens and anabolic growth hormones are hormones that 
contribute to the formation of muscle mass and strength, as we age, 
these hormones also decrease, so that people will lose strength, muscle 
mass, and muscle weakness [12]. Aging, clinically can be attributed to 
weakness in the muscles, fractures occur more easily, and a decrease 
in body mass index results in falls, trauma, infection, the risk of 
delirium, unstable blood pressure, and deterioration of other physical 
conditions [13]. Table 1 is an example of a physical examination of the 
elderly.
Being elderly is a lifelong process that cannot be avoided. It is a 
process of change of the physical, mental, and social. The success of 
health development and life cycle approach that starts from a mother 
preparing her pregnancy until the baby is born, toddlers, school-age 
children and adolescents, adults, and pre-elderly, will determine the 
quantity and the quality of life and health of the elderly in the future. 
If the health services at all stages of the life cycle are done well, it can 
be ascertained that the quality of life in the elderly will be good [15]. 
Individual treatment plans should be done by considering each drug 
pharmacokinetics and pharmacodynamics profile in certain patients 
because the drug can have different reactions in different patients, a 
specific profile should be developed for each patient. Aspects of this 







Pathophysiology of the elderly should be assessed in an integrated 
manner by a health professional collaboration. A series of the 
disease, before and during treatment, family and social history, and 
demographic data need to be examined to assess the health of the 
elderly through geriatric assessment. Approach to medical records and 
physical examination in any very specific geriatric patient, including 
nutrition problems, sight, hearing, urine containment, balance and 
fall prevention, osteoporosis, and polypharmacy should be a concern 
in the treatment of the elderly [17]. The severity of the disease that 
accompanies the aging process in the elderly should be a concern for 
health professionals in assessing their condition. Table 2 provides an 
overview of the relationship between symptoms, diseases, and organ 
disorders.
THE IMPACT CAUSED BY POLYPHARMACY
In general, elderly people suffer from some chronic diseases, 
consequently using a drug that is more complex than other groups of 
age [20]. This group has a condition more severe disease than younger 
adults, due to changes in pharmacokinetics and pharmacodynamics in 
the elderly may affect the metabolism of drugs and drug side effects. 
Often the drugs used in the elderly are often inaccurate, which would be 
associated with health problems, including the incidence of drug side 
effects, and ADRs. Drugs given to the elderly need to be assessed on 
all aspects of elderly patients, taking account of comorbidity, complex 
treatment regimens, functional and cognitive status, the goals of 
therapy, and quality of life. A comprehensive evaluation is needed to 
improve the compliance of drug use in elderly patients were included, 




that is not needed, such as incorrect medication dosage, treatment 
duration and method of use, as well as the clinical effects, including 
interactions with medicines drug or drug-disease
•	 Drugs	without	 indication	 associated	with	 prescription	 drugs	
that are not in accordance with the patient’s clinical condition or 
medications used for clinical treatment, but they are used to prevent 
or prophylaxis against certain other diseases
•	 Indication	without	prescription	relating	to	drugs	clinical	need,	but	not	
given. The impact of polypharmacy in elderly patients as shown in Fig. 1.
Association between polypharmacy and ADEs/ADRs
Multimorbidity and polypharmacy generally will increase the risk of 
ADR. ADR will be difficult to avoid having to consider the treatment of 
patients with possible inappropriate prescribing and potential risk in 
the elderly. Another reason, pharmacokinetic properties may change 
in elderly patients so that the dose needs to be adjusted to avoid the 
incidence of drug side effects [22]. The prevalence of polypharmacy, 
inappropriate prescriptions and ADR interlinked, therefore, should be 
assessed to adjust the drug is needed, so that a given drug needs to pay 
attention to patient safety in elderly patients [23]. The incidence rate of 
polypharmacy, inappropriate prescriptions, and ADR are interrelated. 
The improvement in the quality of the prescription, the selection of 
the appropriate doses, avoids drug-DIs (DDIs), can reduce ADEs. An 
appropriate of prescribing is the key issue to improving drug safety in 
the elderly [24].
Frequent of inappropriate prescription can lead to the risk of falling in 
elderly patients. It is also associated with polypharmacy [25]. Besides, 
to avoid the side effects of medication, dosage, formulation, and 
administration need to be adjusted according to the age and condition 
of the patient, even some certain medication use should be avoided [26]. 
Polypharmacy in elderly patients in Singapore showed that the 
Fig. 1: The impact caused by polypharmacy
Table 1: Summary of age‑related changes in muscle [14]
Reduction in muscle mass (30-40%)
Decreased myosin heavy chain synthesis
Decrease in force
Infiltration of fat into muscle tissue
Increased fatigability
Decrease in basal metabolic rate (decrease up to 4% of decade, after 
50-year-old)
Decreased innervations
Increased number of myofibril per motor unit
Loss or reduced proliferation of satellite cells
Shift toward Type I fibers
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prevalence of the risk of drug-related problems (DRPs) is strongly 
influenced by the numbers of medication received by elderly patients, 
as well as these have the potential risk of occurrence of side effects of 
drugs, and even become one of the causes of the increase of the elderly 
treated in the emergency room in hospital [27]. In a retrospective study 
of the elderly population reported that use of the drug two or three 
types, the potential occurrence of DDIs. Elderly patients who received 
treatment with five or more types of drugs have the potential risk of 
DIs is 4 times greater [28]. Polypharmacy was found to be a significant 
predictor of DDIs-related ADR. The incidence of DDI-related ADRs in 
elderly outpatients was increased with the patient’s age, number of 
diagnosed diseases, and number of drugs consumed [29].
Association between polypharmacy and DRPs
Calderón-Larrañaga et al. [30] suggest that the effect of age on 
ADEs might disappear when the variable level of multimorbidity 
is considered, and the occurrence of ADEs should also take into 
consideration of polypharmacy, include medications administered at a 
hospital or over-the-counter drugs [30]. The chronic health conditions 
and high medication consumption and inadequate drug therapy led to 
various DRPs, particularly related to the patient safety, which caused 
other health problems [31]. Abdullah Al-Hamid and others reported 
that the cardiovascular diseases (CVDs) comprised chronic conditions, 
which required multiple medicine regimens (or polypharmacy), 
and this contributed to DRPs. The hospitalization rate had a higher 
prevalence in patients admitted due to DRPs (12.1%) than patients 
admitted due to ADRs (7%) and ADEs (4.6%). The most DRPs were 
encountered among adult patients admitted with CVDs and diabetes. 
The main causes of hospitalization due to old age and polypharmacy 
were highly represented among patients admitted to hospitals due to 
DRPs [32].
A polypharmacy, non-compliance, and prescription errors were 
underlying reasons for developing DRPs. A few studies classified DRPs 
based on severity and preventability. Few studies classified DRPs based 
on severity and preventability. They reported that the cost for the 
management of DRP was directly proportional to severity. A hospital 
should bring down therapy cost incurred to treat DRP admissions to a 
greater extent (Table 3) [33].
Associated between polypharmacy and PIMs
Polypharmacy is the biggest problem that contributed to the incident 
PIMs, caused to hospitalization, ADEs, particularly among the elderly, 
because of changes in the body’s response and their multimorbidity. 
The greatest risk factor for the elderly is polypharmacy, which is 
associated with drug-related problems, such as adverse effects, poor 
adherence to drug use, DDIs or drug-disease interactions, and the 
high risk of the syndrome geriatric. Polypharmacy is also defined 
as at least one drug delivery a type of medicine there is no clinical 
indication [34]. Below is a describing of correlation polypharmacy in 
geriatric patients. The age of 65 years (elderly), often accompanied by 
multi-pathology of chronic diseases, such as hypertension, diabetes, 
osteoporosis, heart disease, and other degenerative diseases, as it 
Table 2: Review of system organ in elderly [18,19]
System Symptoms Possible problems
Visual Loss of near vision (presbyopia)
Loss of central vision
Loss of peripheral vision
Glare from lights at night
Eye pain
Common with age macular degeneration glaucoma, stroke 
cataracts glaucoma, temporal arteritis
Auditory Hearing loss
Loss of high-frequency range (presbycusis)
Acoustic neuroma, cerumen, Paget’s disease, drug-induced 
ototoxicity common with age
Cardiovascular Difficulty eating or sleeping, over-fatigue, shortness of 
breath, orthopnea
CHF
Pulmonary Chronic cough, shortness of breath Chronic obstructive pulmonary disease
Gastrointestinal Constipation
Fecal incontinence
Chronic obstructive pulmonary disease hypothyroidism, 
dehydration, hypokalemia, colorectal cancer, inadequate 
fiber, inactivity, drugs fecal impaction, rectal carcinoma
Genitourinary Urinary frequency, hesitancy
Urinary incontinence
BPH estrogen deficiency, detrusor instability
Musculoskeletal Proximal muscle pain/weakness Joint pain back pain Polymyalgia rheumatic osteoarthritis, rheumatoid arthritis 
osteoarthritis, osteoporotic compression fracture, cancer
Neurologic/psychiatric Syncope
Transient loss of power, sensation or speech
Persistent aphasia or dysarthria disturbance of gait 
insomnia
Loss of memory extremities
Postural hypotension, seizure, cardiac dysrhythmia, aortic 
stenosis, hypoglycemia transient ischemic attack stroke
Parkinson’s disease, stroke circadian rhythm disturbance, 
drugs, sleep apnea, mood disorder Alzheimer’s disease, 
multi-infarct dementia
Extremities Leg and foot swelling
Leg pain
Osteoarthritis, radiculopathy, intermittent claudication, 
night cramps CHF, venous insufficiency
BPH: Benign prostatic hyperplasia, CHF: Congestive heart failure
Table 3: Categories of DRPs [3]
Problem Description
Drug use without 
indication
The patient get a drug for treatment no 
needed for medically indication
ADR The patient has a medical problem that is 
the result of an ADR or adverse effect
DIs The patient has a medical problem by the 
resulting of DDI or drug-disease interaction
Overdose or 
sub-therapeutic dose
The patient receive too much or too little 




The patient receive some drug treatment 
for longer period of time than clinically 
indicated
Untreated condition The patient has a medical problem that 
requires drug therapy but is not receiving a 
drug for that condition
Clinical 
contraindication
Use of a drug which is contraindicated for 




Use of multiple drugs with similar 
pharmacological effect when single drug is 
adequate
47
Asian J Pharm Clin Res, Vol 10, Issue 7, 2017, 44-49
 Fauziyah et al. 
also issues of independence and dependence properties, function 
and dysfunction of organs. Aging is a multidimensional process. 
Normal aging and diseases associated with aging are two separate 
conditions. Associated with the normal aging processes that decrease 
in physiological functions in living organisms, for example, bone loss, 
osteoarthritis, and cataracts. Diseases associated with aging, but not 
caused by aging and do not occur in all people (including probabilistic 
aging) including dementia, hypothyroidism, stroke, and CHF [10]. 
Administration of drugs in elderly individuals should take into 
account the physiological changes due to aging patients where there 
would be changes in the pharmacokinetics (absorption, distribution, 




handling and administering their drugs [37]
•	 Multi-dose	users	may	be	more	exposed	to	potentially	inappropriate	
drug use than ordinary prescription users
•	 However,	multi-dose	users	 seem	 to	have	a	 lower	probability	of	
potentially serious DIs
•	 Younger	elderly	with	multi-dose	drug	dispensing	may	have	the	most	
problems with potentially inappropriate drug use (Table 4).
CONCLUSION
Polypharmacy in elderly patients is often difficult to avoid because it is 
associated with a number of diseases suffered by the elderly. Therefore, 
inappropriate prescribing is an important concern of health workers to 
avoid unwanted drug effects.
Administration of drugs in the elderly should pay attention to the 
pharmacokinetics and pharmacodynamics of drugs especially the 
adjustment of drug dose to avoid drug side effects and DIs. Elderly patients 
were given five or more medications, need to be closely monitored 
because they are four times higher risk of undesired effects due to DIs. 
The role of pharmacists in assessing polypharmacy in elderly patients 
is very important. Collaboration between the medical profession needs 
to be done to evaluate the best treatment outcomes in elderly patients. 
Elderly patients with multiple diseases, it may get more types of drugs 
in polypharmacy, and potentially increase the inappropriate prescription 
drugs, and contributes to ADEs, ADRs, and duration of hospitalization.
Country, period Method of research; number of samples; 
number of drugs






The retrospective observational of 
1027	patients	aged	≥65	years.	The	mean	of	
comorbidities was 2.96±1.286, and prevalence 
of polypharmacy was 85%




An aging can lead to an increasing 
of polypharmacy. The comorbidity 
affects the level of PIMs so that the 
increasing of PIMs number will 




The cross-sectional design of 731,105 older 
people	aged	≥75	years.	The	mean	number	of	
polypharmacy, 4.7±3.3 (women), 4.5±3.2 (men)
Sjoqvist system The multi-dose use can more 
exposed to potential IDU
[37]
May 2013 and 
June 2013, Japan






The prevalence of IP among 
elderly home care and the risk 
factors for IP were associated 
of polypharmacy and specific 
underlying medical conditions
[39]
Singapore, 2004 A randomly selected of 454 patients elderly 
age >65 years. The mean prevalence of 
polypharmacy was 6.4
HCFA The prevalence of polypharmacy 
use and PIMs are high in nursing 
homes, thus more medication used 
may lead to significant ADRs and 
Dis
[3]
A period of 3 
months, Austrian
A monocentric prospective cohort study from 
543 patients. The mean number of drugs was 
7.5±3.8, unnecessary drugs were 36.3%, drugs 
to avoid in 30.1%, duplication in 7.6%, wrong 
dosage in 23.4% and possible DDIs in 65.8%. 
ADEs were identified in 17.8%
Beers criteria Polypharmacy, IP, and ADEs were 
highly prevalent in elderly. Risk 
factors for ADEs were female sex, 
poly-morbidity, renal dysfunction 
and inappropriate prescribing. To 
improve drug safety, appropriate 
prescribing might be more 
important than simply reducing the 
number of prescribed drugs
[24]
July 2004 and June 
2005, Israel
A retrospective observational of 1027 patients 
aged	≥65	years.	The	mean	of	chronic	disease	
was 6.3±2.6, and prevalence of polypharmacy 
was 5.95±2.4
MMSE No relationship was found between 
IPDs on discharge and age, sex, 
functional status, cognitive level, 
number of chronic diseases, and 
cause of admission
[40]
Ireland in 2007 A retrospective national population 
study (n=338,801) using, PIPs 27.392 (8%) 
were prescribed two and 10.103 (3%) were 
prescribed three or more. PPIs at maximum 
therapeutic dosage for >8 weeks was prescribed 
PIMs (56.560, 17%)
STOPP criteria Polypharmacy was strongly 
associated with PIP
[41]
23 January and 13 
February 2013, 
Japan
The cohort of 2053 elderly patients aged 
≥65	 years,	 the	 average	 was	 48.4%	 of	 patients	
were defined as PIMs. The PIM-induced ADEs 
were 8% of patients
“Beers Criteria: The 
Japanese V.2003”
The PIM prevalence associated with 
home health care was relatively 
high
[42]
Table 4: The impact of polypharmacy and PIMs among elderly
(Contd...)
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